Besides blocking the VEGF pathway with VEGF antibodies, the angiogenic pathway can be targeted with small molecule VEGFR tyrosine kinase inhibitors (TKIs)—those currently used in ovarian cancer include, sorafenib, sunitinib cediranib, vandetanib, and intedanib (BIBF 1120) [7, 15, 65, 153, 154, 162, 164–166]. The gene discussed is VEGFA; the disease is ovarian carcinoma.